| Pair Name | Wogonin, Doxorubicin | ||
| Phytochemical Name | Wogonin (PubChem CID: 5281703 ) | ||
| Anticancer drug Name | Doxorubicin (PubChem CID: 31703 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Wogonin, Doxorubicin | |||
| Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
| Gene Regulation | Down-regulation | Expression | NFE2L2 | hsa4780 |
| In Vitro Model | MCF-7(DOX/R) | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_C4M9 |
| Result | Wogonin reversed drug resistance and its reversal mechanism might be due to the suppression of Nrf2 signaling pathway, indicating the feasibility of using Nrf2 inhibitors to increase efficacy of chemotherapeutic drugs. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Drug resistance associates with activation of Nrf2 in MCF-7/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response. Mol Carcinog. 2013;52(10):824-834. doi:10.1002/mc.21921 | Click |
